Canada approves AMDL's cancer blood test:
This article was originally published in Clinica
Executive Summary
Theranostics company AMDL has gained the go-ahead to market its cancer blood test, DR-70, in Canada. The test can detect up to 13 cancers using a single tube of blood, reducing the need for costly, multiple tests, says the Tustin, California firm. "Already, several potential distributors have shown serious interest in the Canadian market and AMDL can now accelerate those discussions," said Gary Dreher, the company's president and CEO.